Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Celularity ( (CELU) ).
Celularity Inc. entered into a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. on August 5, 2025, involving the issuance of 7,198.630 shares of Series Seed-2 Preferred Stock in exchange for $2,890,250 of product purchase credits. Additionally, Celularity faced compliance issues with Nasdaq due to a delay in filing its quarterly report for the quarter ended March 31, 2025. The company submitted a compliance plan on August 1, 2025, and was given until August 31, 2025, to file the necessary reports to avoid delisting.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Neutral.
The stock’s overall score is driven by strong technical momentum, despite weak financial performance and unattractive valuation. The company’s high leverage and negative cash flows are areas of concern, but recent price momentum indicates investor interest.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Average Trading Volume: 249,975
Technical Sentiment Signal: Buy
Current Market Cap: $77.36M
See more data about CELU stock on TipRanks’ Stock Analysis page.